www.medbiogene.com/EN/2006/med_biogene_appoints_john_h. -
[Cached Version]
Published on: 10/12/2008
Last Visited: 6/15/2008
Med BioGene Appoints John H. Rayson, M.D. as Chairman of the Board; Reports Financial Results for Third Quarter 2006November 29, 2006
VANCOUVER, BRITISH COLUMBIA - Med BioGene Inc. (TSX Venture: MBI), an emerging biotechnology company developing genetic biomarkers for use in improving diagnosis, prognosis and treatment decisions for patients suffering from certain cancers and cardiovascular disease, today reported that it appointed John H. Rayson, M.D. as its new Chairman of the Board and further reported its financial results for the three months ending September 30, 2006.
APPOINTMENT OF JOHN H. RAYSON, M.D. AS CHAIRMAN OF THE BOARD
The Board of Directors of MBI on November 25, 2006 appointed John H. Rayson as its new Chairman of the Board, replacing the founder of MBI and its President and Chief Scientific Officer, Dr. T. Nathan Yoganathan.
...
Dr. Yoganathan stated "We are very pleased that Dr. Rayson has accepted the appointment of Chairman.
...
Dr. Rayson's experience and accomplishments in the industry are invaluable in assisting Med BioGene's efforts to develop its genetic biomarkers and his increased role with the company as Chairman is consistent with our commitment to the highest corporate governance standards."
Dr. Rayson has been a director of MBI since 2004.Dr. Rayson practiced family medicine for 27 years before joining MDS Metro Laboratory Services in 1994 as President and Chief Executive Officer, a position he held until 2001 when he became Chief Executive Officer and Executive Vice Chairman.Dr. Rayson retired as CEO in June 2006 but continues as Executive Vice Chairman.